FTC Broadens Notification Requirements for Transfers of Pharmaceutical Patent Rights

by Bracewell LLP
Contact

The Federal Trade Commission (FTC) has revised the rule for determining when a transfer of exclusive rights to a patent in the pharmaceutical industry (including biologics and medicine manufacturing) results in a potentially reportable asset acquisition under the Hart-Scott-Rodino (HSR) Act. The new rule will go into effect 30 days after publication in the Federal Register.

The HSR Act established the premerger notification program, which requires parties to mergers and acquisitions that meet certain size thresholds to make a filing with the federal antitrust agencies, the FTC and the Department of Justice, and observe a waiting period before consummating such reportable transactions. The FTC has long taken the position that the grant of an exclusive patent license is a potentially reportable asset acquisition under the HSR Act, since it is functionally equivalent to the sale of a patent. 

Under previous FTC interpretations, exclusive patent licenses were only reportable if they gave the licensee all rights to "make, use, and sell" the patented product. Under the new rule, which applies only to the pharmaceutical industry, a license (or other form of transfer) that gives the licensee "all commercially significant rights" to a pharmaceutical patent "for any therapeutic area (or specific indication within a therapeutic area)" is a potentially reportable asset acquisition. The FTC explains that a therapeutic area covers the intended use for a patent or a part thereof (such as neurological use, for example), while an indication encompasses a narrower segment of a therapeutic area (such as Alzheimer’s disease). Such exclusive licenses may be reportable even where the patent holder retains a right to manufacture the product for the licensee, or retains various co-rights to assist the licensee in developing and commercializing the patented drug.

According to the FTC, the new rule is designed to address the evolution of pharmaceutical patent licenses, since it has become more common for pharmaceutical companies to retain some rights. Under the old test, for example, deals in which the patent owner keeps the right to manufacture the drug for its exclusive licensee were not subject to review under the HSR Act.  Now such deals are potentially notifiable.  The new rule thus provides the antitrust agencies with an opportunity to assess under the HSR Act the competitive impact of exclusive pharmaceutical patent licenses that may not have been reportable under the prior approach.

A highly unusual feature of the new HSR rule is that it is limited to a single industry. The FTC justifies this approach by noting that the pharmaceutical sector is the only industry where it has seen these types of exclusive patent licenses in the past five years. However, the agency leaves open the possibility that it may adopt a similar rule for other industries in the future and states that even in the absence of such a specific rule, exclusive patent licenses in other industries remain potentially reportable under the HSR Act. This could lead to greater uncertainty, although parties to such a transaction outside of the pharmaceutical area (or their counsel) can contact the FTC for advice.

In light of the new rule, pharmaceutical companies will need to reassess whether their exclusive licensing deals are required to be notified under the HSR Act. For transactions that are determined to be reportable, they will also need to factor in the time and cost of preparing an HSR filing, as well as the mandatory 30-day waiting period before the transaction can close.

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Bracewell LLP | Attorney Advertising

Written by:

Bracewell LLP
Contact
more
less

Bracewell LLP on:

Readers' Choice 2017
Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign up using*

Already signed up? Log in here

*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
Privacy Policy (Updated: October 8, 2015):
hide

JD Supra provides users with access to its legal industry publishing services (the "Service") through its website (the "Website") as well as through other sources. Our policies with regard to data collection and use of personal information of users of the Service, regardless of the manner in which users access the Service, and visitors to the Website are set forth in this statement ("Policy"). By using the Service, you signify your acceptance of this Policy.

Information Collection and Use by JD Supra

JD Supra collects users' names, companies, titles, e-mail address and industry. JD Supra also tracks the pages that users visit, logs IP addresses and aggregates non-personally identifiable user data and browser type. This data is gathered using cookies and other technologies.

The information and data collected is used to authenticate users and to send notifications relating to the Service, including email alerts to which users have subscribed; to manage the Service and Website, to improve the Service and to customize the user's experience. This information is also provided to the authors of the content to give them insight into their readership and help them to improve their content, so that it is most useful for our users.

JD Supra does not sell, rent or otherwise provide your details to third parties, other than to the authors of the content on JD Supra.

If you prefer not to enable cookies, you may change your browser settings to disable cookies; however, please note that rejecting cookies while visiting the Website may result in certain parts of the Website not operating correctly or as efficiently as if cookies were allowed.

Email Choice/Opt-out

Users who opt in to receive emails may choose to no longer receive e-mail updates and newsletters by selecting the "opt-out of future email" option in the email they receive from JD Supra or in their JD Supra account management screen.

Security

JD Supra takes reasonable precautions to insure that user information is kept private. We restrict access to user information to those individuals who reasonably need access to perform their job functions, such as our third party email service, customer service personnel and technical staff. However, please note that no method of transmitting or storing data is completely secure and we cannot guarantee the security of user information. Unauthorized entry or use, hardware or software failure, and other factors may compromise the security of user information at any time.

If you have reason to believe that your interaction with us is no longer secure, you must immediately notify us of the problem by contacting us at info@jdsupra.com. In the unlikely event that we believe that the security of your user information in our possession or control may have been compromised, we may seek to notify you of that development and, if so, will endeavor to do so as promptly as practicable under the circumstances.

Sharing and Disclosure of Information JD Supra Collects

Except as otherwise described in this privacy statement, JD Supra will not disclose personal information to any third party unless we believe that disclosure is necessary to: (1) comply with applicable laws; (2) respond to governmental inquiries or requests; (3) comply with valid legal process; (4) protect the rights, privacy, safety or property of JD Supra, users of the Service, Website visitors or the public; (5) permit us to pursue available remedies or limit the damages that we may sustain; and (6) enforce our Terms & Conditions of Use.

In the event there is a change in the corporate structure of JD Supra such as, but not limited to, merger, consolidation, sale, liquidation or transfer of substantial assets, JD Supra may, in its sole discretion, transfer, sell or assign information collected on and through the Service to one or more affiliated or unaffiliated third parties.

Links to Other Websites

This Website and the Service may contain links to other websites. The operator of such other websites may collect information about you, including through cookies or other technologies. If you are using the Service through the Website and link to another site, you will leave the Website and this Policy will not apply to your use of and activity on those other sites. We encourage you to read the legal notices posted on those sites, including their privacy policies. We shall have no responsibility or liability for your visitation to, and the data collection and use practices of, such other sites. This Policy applies solely to the information collected in connection with your use of this Website and does not apply to any practices conducted offline or in connection with any other websites.

Changes in Our Privacy Policy

We reserve the right to change this Policy at any time. Please refer to the date at the top of this page to determine when this Policy was last revised. Any changes to our privacy policy will become effective upon posting of the revised policy on the Website. By continuing to use the Service or Website following such changes, you will be deemed to have agreed to such changes. If you do not agree with the terms of this Policy, as it may be amended from time to time, in whole or part, please do not continue using the Service or the Website.

Contacting JD Supra

If you have any questions about this privacy statement, the practices of this site, your dealings with this Web site, or if you would like to change any of the information you have provided to us, please contact us at: info@jdsupra.com.

- hide
*With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name. Or, sign up using your email address.